1682 completed, 194 terminated, 177 unknown, 94 recruiting. 2303 Phase 3, 285 Phase 2.
Follow Glucose Metabolism Disorders: new trials by email Literature Review of Glucose Metabolism Disorders trials Research Report on Glucose Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| Verapamil In Preclinical Type 1 Diabetes Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2027-01-01 | 2026-10-22 |
| Diabetes Prevention Through Genetics, Familial History and Behavior Change LEGACY DPP, DPP - Prediabetes, Weight Loss | Phase 2 / Phase 3 | Not yet recruiting | Morehouse School of Medicine | 400 | 2027-01-01 | 2026-10-20 |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 948 | 2026-12-01 | 2026-10-22 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk Eloralintide, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 3000 | 2026-12-01 | 2026-10-28 |
| iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) N0892, Januvia® + Glifage XR® + Placebo, Forxiga® + Glifage XR® + Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-11-30 | 2025-12-18 | |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 1500 | 2026-11-06 | 2026-10-02 |
| Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Maridebart cafraglutide, Semaglutide - Diabetes Mellitus, Type 2 | Phase 3 | Not yet recruiting | Amgen | 1300 | 2026-11-02 | 2026-10-08 |
| A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes eloralintide and tirzepatide, Tirzepatide - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 1000 | 2026-11-01 | 2026-10-19 |
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Semaglutide, Placebo - Type 1 Diabetes, Overweight , Obesity | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 40 | 2026-10-13 | 2026-10-23 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Petrelintide, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 3 | Recruiting | Hoffmann-La Roche | 600 | 2026-09-30 | 2026-10-07 |
| A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy AD-233A, AD-233B, AD-233C - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Not yet recruiting | Addpharma Inc. | 354 | 2026-09-30 | 2026-09-16 |
| A Study of BGM0504 in Early T2DM With Obesity BGM0504, semaglutide - Type 2 Diabetes (T2DM) | Phase 3 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | 372 | 2026-09-17 | 2026-10-13 |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema CagriSema - Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | Novo Nordisk A/S | 210 | 2026-09-16 | 2026-09-30 |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） UBT251 Injection 2.0 mg, UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg - Type 2 Diabetes | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 360 | 2026-09-07 | 2026-09-15 |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group - Type 2 Diabetes | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 956 | 2026-09-07 | 2026-09-14 |
| BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes Bofanglutide, Semaglutide - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Not yet recruiting | Carnot Laboratories | 374 | 2026-09-01 | 2026-06-05 |
| Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-09-01 | 2025-12-18 |
Showing 20 of 2303. Sign in to see all of them.
Diabetes Mellitus, Type 2 (1426) · Diabetes Mellitus (781) · Diabetes Mellitus, Type 1 (316) · Insulin Resistance (178) · Obesity (145) · Metabolic Syndrome (105) · Hypertension (78) · Dyslipidemias (62) · Cardiovascular Diseases (59) · Overweight (56) · Hyperglycemia (55) · Hypoglycemia (52) · Glucose Intolerance (39) · Prediabetic State (39)
Nutritional and Metabolic Diseases (2300) · Metabolic Diseases (2271) · Endocrine System Diseases (2100) · Diabetes Mellitus (1326) · Immune System Diseases (329) · Pathological Conditions, Signs and Symptoms (323) · Autoimmune Diseases (317) · Hyperinsulinism (277) · Signs and Symptoms (219) · Vascular Diseases (194) · Cardiovascular Diseases (182) · Body Weight (160) · Nutrition Disorders (159) · Overnutrition (157)
Metformin (320) · Insulin Glargine (192) · Sitagliptin Phosphate (132) · Insulin Aspart (92) · semaglutide (89) · dapagliflozin (87) · glimepiride (82) · Pioglitazone (81) · Vildagliptin (76) · Insulin (74) · Liraglutide (71) · Exenatide (59) · insulin degludec (59) · empagliflozin (54) · Insulin Lispro (53)
Novo Nordisk A/S (229) · AstraZeneca (138) · Eli Lilly and Company (122) · Sanofi (105) · Merck Sharp & Dohme LLC (89) · Takeda (64) · Boehringer Ingelheim (52) · Novartis (38) · Novartis Pharmaceuticals (37) · GlaxoSmithKline (33) · Hoffmann-La Roche (22) · Pfizer (20) · Ain Shams University (17) · Astellas Pharma Inc (14) · Lexicon Pharmaceuticals (14)
United States (938) · Canada (394) · Germany (390) · Mexico (319) · Spain (279) · Poland (274) · United Kingdom (260) · China (242) · India (238) · Russia (238) · Japan (237) · Italy (236) · France (231) · Hungary (222) · South Korea (216)
PMID 38770818, PMID 39963952, PMID 22236356, PMID 31903692, PMID 32998732, PMID 35044568, PMID 22913891, PMID 38682786, PMID 23010561, PMID 25504028, PMID 32267058, PMID 26580237, PMID 26894924, PMID 27402391, PMID 35472672, PMID 24517339, PMID 31606880, PMID 32306296, PMID 21450987, PMID 21883806, PMID 22193143, PMID 22234149, PMID 22862847, PMID 23130654, PMID 23186975, PMID 24170235, PMID 24786834, PMID 26232910, PMID 27977934, PMID 30615985, PMID 30880443, PMID 31769496, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32501595, PMID 32648108, PMID 36542287, PMID 17878242, PMID 18093207, PMID 19245711, PMID 19491536, PMID 21209033, PMID 22055210, PMID 23748506, PMID 24561125, PMID 26121451, PMID 26691396, PMID 27161178
2008 (33), 2009 (33), 2015 (26), 2025 (24), 2014 (23), 2016 (21), 2005 (18), 2017 (15), 2018 (14), 2019 (9), 2023 (9), 2004 (4), U01DK048489 (2), U01DK074556 (2), U01DK094406 (2)